These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 39046895)

  • 1. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.
    Dy GK; Farooq AV; Kang JJ
    Oncologist; 2024 Jul; ():. PubMed ID: 39046895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
    Lindgren ES; Yan R; Cil O; Verkman AS; Chan MF; Seitzman GD; Farooq AV; Huppert LA; Rugo HS; Pohlmann PR; Lu J; Esserman LJ; Pasricha ND
    Curr Ophthalmol Rep; 2024 Jun; 12(2):13-22. PubMed ID: 38756824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.
    Eaton JS; Miller PE; Mannis MJ; Murphy CJ
    J Ocul Pharmacol Ther; 2015 Dec; 31(10):589-604. PubMed ID: 26539624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.
    Hendershot A; Slabaugh M; Riaz KM; Moore KN; O'Malley DM; Matulonis U; Konecny GE
    Gynecol Oncol Rep; 2023 Jun; 47():101155. PubMed ID: 37102083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
    Tang L; Sun C; Liu W; Wu H; Ding C
    Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
    Li J; Shen G; Liu Z; Liu Y; Wang M; Zhao F; Ren D; Xie Q; Li Z; Liu Z; Zhao Y; Ma F; Liu X; Xu Z; Zhao J
    Cancer Innov; 2023 Oct; 2(5):346-375. PubMed ID: 38090386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.
    Long P; Li S; Pan L; Wang Y; Chen W; Wang X
    Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
    Nguyen TD; Bordeau BM; Balthasar JP
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates.
    Nadkarni DV; Lee J; Jiang Q; Patel V; Sriskanda V; Dutta K; Meyer DM
    Mol Pharm; 2021 Mar; 18(3):889-897. PubMed ID: 33470823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
    Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
    Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
    Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
    Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular toxicities associated with antibody drug conjugates.
    Marshall RF; Xu H; Berkenstock M
    Curr Opin Ophthalmol; 2024 Nov; 35(6):494-498. PubMed ID: 38814581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical cyclosporine A therapy for dry eye syndrome.
    de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(1):1-90. PubMed ID: 23074513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):741-762. PubMed ID: 37460440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.
    Liu SH; Hawkins BS; Ng SM; Ren M; Leslie L; Han G; Kuo IC
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013520. PubMed ID: 35238405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.